Skip to main content
Clinical Trials/CTRI/2015/10/006247
CTRI/2015/10/006247
Active, not recruiting
Phase 4

A prospective, Post Marketing Surveillance study to study the safety and effectiveness of omalizumab in Indian patients with Chronic Spontaneous Urticaria refractory to standard of care

ovartis Healthcare Private Limited0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: null- Xolair in CS
Sponsor
ovartis Healthcare Private Limited
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
ovartis Healthcare Private Limited

Eligibility Criteria

Inclusion Criteria

  • 1\. CSU patients prescribed with omalizumab as per approved package insert and who are not treated with omalizumab 6 months prior to entering the study.
  • 2\. Patients willing to participate in the study by providing written informed consent.

Exclusion Criteria

  • 1\.Contraindication as per PI.
  • 2\.Patients simultaneously participating in other studies
  • Pregnant women should not be included except if, in the opinion of the investigator, the expected benefit outweighs the potential risk to the fetus.

Outcomes

Primary Outcomes

Not specified

Similar Trials